<DOC>
	<DOCNO>NCT00171938</DOCNO>
	<brief_summary>This open label clinical trial imatinib mesylate 800 mg po/day population patient unresectable , recurrent glioblastoma multiforme . Patients treat 12 month</brief_summary>
	<brief_title>Open-label Trial Imatinib Mesylate Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR ( Platelet Derived Growth Factor Receptors )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Histologically documented diagnosis GBM . 2 . Immunohistochemical documentation expression PDGFR . 3 . Unresectable , recurrent disease MRI spectroscopy 1 . Treatment investigational agent within 28 day first day study drug dose . 2 . Concurrent chemotherapy . 3 . Concurrent radiotherapy . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Imatinib</keyword>
	<keyword>PDGFR</keyword>
</DOC>